Skip to main content

Table 2 Production cost and profits made from lamivudine 150 mg plus zidovudine 300 mg tablets

From: Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market

Materials cost Zidovudine Lamivudine
Daily dose (mg) 600 300
Amount of API per person-year in kg (daily dose in mg X 365 days/1.000.000) 0.219 0.1095
Cost of API (per kg) (lowest quote in the 2010 WHO survey) 315 150
Cost of API per person-year (Amount of API per person-year in kg X cost of API per kg) 69.0 16.4
Cost of API per person-year of both APIs combined 85.4
Number of tablets/day required to administer a daily dose of zidovudine plus lamivudine 2
Cost of excipients and packaging (3.21 per 365 tablets X number of tablets/day X 365 days) 6.4
Subtotal materials cost per person-year 91.8
Non-materials cost per person-year (according to both scenarios) Indian manufacturer Publicly owned manufacturer
Indian manufacturer: 78.3% of materials cost 71.9 -
Publicly owned manufacturer: 23.4 X number of tablets/day - 46.8
Total production cost per person-year   
Materials cost PLUS non-materials cost 163.7 138.6
Median price paid by low income countries per person- year in 2010 101.4
Profit or loss per person-year at API cost quoted to WHO in 2010 −62.3 −37.2
Profit or loss per person-year when API cost is:   
20% less than quoted to WHO −31.9 −20.1
40% less than quoted to WHO −1.4 −3.1
60% less than quoted to WHO 29.0 14.0
  1. (amounts in $US).